HLB Therapeutics Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
49
- Stock Symbol
-
115450
- Investments
-
3
- Share Price
-
$1.22
- (As of Monday Closing)
HLB Therapeutics General Information
Description
HLB Therapeutics Co Ltd is a biotech company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a biopharmaceutical company focused on alleviating patient suffering.
Contact Information
Website
www.hlbtherapeutics.comCorporate Office
- 22F, Parkview Office Tower
- 248, Jeongjail-ro, Bundang-gu
- Seongnam, Gyeonggi 13554
- South Korea
Corporate Office
- 22F, Parkview Office Tower
- 248, Jeongjail-ro, Bundang-gu
- Seongnam, Gyeonggi 13554
- South Korea
HLB Therapeutics Timeline
HLB Therapeutics Stock Performance
As of 16-Nov-2026, HLB Therapeutics’s stock price is $1.22. Its current market cap is $108M with 88.1M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.22 | $1.75 | $0.89 - $2.83 | $108M | 88.1M | 689K | -$0.14 |
HLB Therapeutics Financials Summary
As of 30-Jun-2026, HLB Therapeutics has a trailing 12-month revenue of $44.4M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 161,606 | 188,209 | 641,486 | 243,125 |
| Revenue | 44,408 | 48,879 | 40,260 | 40,224 |
| EBITDA | (11,356) | (3,645) | (10,154) | 4,176 |
| Net Income | (12,418) | (6,483) | (16,705) | (1,761) |
| Total Assets | 143,041 | 158,787 | 149,218 | 155,814 |
| Total Debt | 26,206 | 28,160 | 15,854 | 7,777 |
HLB Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
HLB Therapeutics Signals
HLB Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
HLB Therapeutics Investments & Acquisitions (3)
HLB Therapeutics’s most recent deal was a PIPE with HLB Genex for . The deal was made on 12-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HLB Genex | 12-Dec-2024 | PIPE | Drug Discovery | ||
| HLB Panagene (Biotechnology) | 21-Jun-2023 | Merger/Acquisition | Biotechnology | ||
| HLB Panagene (Biotechnology) | 20-Jun-2023 | PIPE | Biotechnology |
HLB Therapeutics ESG
Risk Overview
Risk Rating
Updated June, 30, 2025
31.3 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
HLB Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| HLB Panagene (Biotechnology) | Daejeon, South Korea | 1976 |
HLB Therapeutics FAQs
-
When was HLB Therapeutics founded?
HLB Therapeutics was founded in 2000.
-
Where is HLB Therapeutics headquartered?
HLB Therapeutics is headquartered in Seongnam, South Korea.
-
What is the size of HLB Therapeutics?
HLB Therapeutics has 49 total employees.
-
What industry is HLB Therapeutics in?
HLB Therapeutics’s primary industry is Drug Discovery.
-
Is HLB Therapeutics a private or public company?
HLB Therapeutics is a Public company.
-
What is HLB Therapeutics’s stock symbol?
The ticker symbol for HLB Therapeutics is 115450.
-
What is the current stock price of HLB Therapeutics?
As of 16-Nov-2026 the stock price of HLB Therapeutics is $1.22.
-
What is the current market cap of HLB Therapeutics?
The current market capitalization of HLB Therapeutics is $108M.
-
What is HLB Therapeutics’s current revenue?
The trailing twelve month revenue for HLB Therapeutics is $44.4M.
-
What is HLB Therapeutics’s annual earnings per share (EPS)?
HLB Therapeutics’s EPS for 12 months was -$0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process